×

RSS Feed Info

This link opens your blog's RSS feed in XML format.

To subscribe, copy and paste this link into your RSS reader:

https://jay-alam.quarto.pub/javaid-alam/blog.xml

You can use free apps like Feedly, Inoreader, or NetNewsWire.

Severe Trimethoprim-Associated Hyperkalaemia in an Older Adult Receiving Lisinopril and Spironolactone

Published

June 15, 2026

Patient Background

Mr. Peter Morgan is a 77-year-old male with a medical history of hypertension, coronary artery disease, type 2 diabetes mellitus, hyperlipidaemia, and pulmonary hypertension.

His long-term medications included:

Current Medication Regimen
Medication Dose Frequency
Diazepam 5 mg At night
Amlodipine 5 mg Once daily
Digoxin 125 micrograms Once daily
Atorvastatin 40 mg At night
Spironolactone 25 mg Once daily
Glipizide 5 mg Once daily before breakfast
Metoprolol succinate 50 mg Once daily
Clopidogrel 75 mg Once daily
Lisinopril 20 mg Once daily
Aspirin 81 mg Once daily
Nitroglycerin 0.4 mg sublingual As required for angina

Five days before presentation, he had been prescribed trimethoprim–sulfamethoxazole for presumed bacterial sinusitis. No adjustment was made to his existing lisinopril or spironolactone therapy, and no early electrolyte monitoring was arranged.

Clinical Presentation

Mr. Morgan presented to the emergency department with progressive generalized weakness, lethargy, and reduced exercise tolerance. He denied chest pain but reported feeling unusually fatigued over the preceding two days.

On assessment, his heart rate was markedly reduced at 43 beats/minute. Electrocardiography demonstrated prominent peaked T waves, raising immediate concern for clinically significant hyperkalaemia.

Initial laboratory investigations demonstrated:

  • Potassium: 7.3 mmol/L
  • Sodium: 125 mmol/L
  • Digoxin concentration: 1.2 ng/mL

The combination of profound hyperkalaemia, ECG abnormalities, and bradycardia represented a potentially life-threatening medication-related emergency.

Clinical Issue Identified

Comprehensive medication review identified a high-risk pharmacodynamic interaction involving trimethoprim, lisinopril, and spironolactone.

Trimethoprim has an amiloride-like effect within the distal nephron, inhibiting epithelial sodium channels and thereby reducing the electrochemical gradient required for renal potassium secretion. The result is impaired potassium elimination and potentially substantial hyperkalaemia.

This effect was superimposed on two chronic potassium-retaining medications. Lisinopril reduces angiotensin II–mediated aldosterone secretion, while spironolactone directly antagonizes aldosterone receptors. The addition of trimethoprim therefore created multiple simultaneous mechanisms impairing renal potassium excretion.

The likely pharmacological sequence was:

Lisinopril + spironolactone → reduced potassium excretion → trimethoprim added → additional ENaC blockade → severe hyperkalaemia → cardiac conduction disturbance and symptomatic bradycardia.

The patient’s metoprolol and digoxin were also clinically relevant. Although therapeutic digoxin should not be considered a primary cause of the hyperkalaemia in this case, both digoxin and metoprolol can slow cardiac conduction and may increase the clinical consequences of severe hyperkalaemia. Trimethoprim–sulfamethoxazole may also increase digoxin concentrations in older adults, making monitoring appropriate.

The accompanying hyponatraemia also warranted evaluation. Trimethoprim can promote renal sodium loss through its distal tubular effects, although other causes of hyponatraemia should also be excluded. Current product information recognises both hyperkalaemia and clinically significant hyponatraemia as potential adverse effects of trimethoprim–sulfamethoxazole.

Pharmacist Intervention and Clinical Management

Treat severe hyperkalaemia as a medical emergency

Mr. Morgan required continuous cardiac monitoring and immediate treatment of hyperkalaemia. Because ECG abnormalities were present, intravenous calcium would be appropriate to stabilise the cardiac membrane, followed by therapies that temporarily shift potassium intracellularly, such as intravenous insulin with glucose and, where appropriate, a nebulised β2-agonist.

Definitive potassium removal should then be achieved according to renal function, volume status, response to initial treatment, and overall clinical condition. Serial potassium measurements and repeat ECGs are required until the potassium concentration and cardiac abnormalities have stabilised.

Immediately discontinue trimethoprim–sulfamethoxazole

The recently introduced antibiotic should be considered the principal precipitating medication and discontinued.

The indication for antibiotic treatment should also be reassessed. If antimicrobial therapy remains necessary, an alternative antibiotic without clinically significant potassium-retaining effects should be selected according to the suspected infection, microbiology, allergy history, renal function, and local antimicrobial guidelines.

Temporarily withhold potassium-raising medications

Lisinopril and spironolactone should be withheld during the acute hyperkalaemic episode. Their long-term indications should subsequently be reassessed once potassium and renal function have stabilised.

Reintroduction, if clinically necessary, should occur cautiously with follow-up monitoring of potassium and renal function.

Review medications contributing to bradycardia

Given a heart rate of 43 beats/minute, metoprolol and digoxin should be temporarily reviewed or withheld as clinically appropriate while the cause of bradycardia is evaluated.

The digoxin concentration should be interpreted in conjunction with renal function, the indication for therapy, clinical features of toxicity, and ECG findings rather than relying solely on the measured concentration.

Evaluate renal function and contributing physiological factors

Urgent assessment should include serum creatinine, estimated glomerular filtration rate, bicarbonate, magnesium, glucose, and volume status.

Renal impairment would substantially increase the risk associated with this combination because reduced renal clearance magnifies the potassium-retaining effects of trimethoprim, ACE inhibition, and mineralocorticoid receptor antagonism.

Investigate and correct the hyponatraemia

The serum sodium of 125 mmol/L requires assessment of symptom severity, volume status, serum and urine osmolality, urine sodium, glucose, and other potential medication or disease-related causes.

Correction should be guided by the underlying mechanism and undertaken cautiously to avoid overly rapid changes in serum sodium.

7. Establish a future interaction-prevention plan

The medication record should document trimethoprim–sulfamethoxazole as a high-risk medication in the context of concurrent ACE inhibitor and spironolactone therapy.

If trimethoprim is ever considered unavoidable, baseline renal function and potassium should be assessed, the necessity of other potassium-raising medications reviewed, and serum potassium monitored early during therapy. Current product information specifically advises close potassium monitoring when trimethoprim is combined with medications known to cause hyperkalaemia.

Clinical Rationale and Ramifications

This case demonstrates how a relatively common antibiotic can precipitate a life-threatening electrolyte disturbance when added to an already potassium-retaining medication regimen. Lisinopril and spironolactone had created a background susceptibility to hyperkalaemia, while the introduction of trimethoprim provided an additional mechanism of impaired renal potassium secretion. The interaction is clinically important because severe hyperkalaemia can produce bradyarrhythmias, conduction disturbances, ventricular arrhythmias, cardiac arrest, and sudden death. In older patients taking spironolactone, trimethoprim–sulfamethoxazole has been associated with a markedly increased risk of hospital admission for hyperkalaemia.

Population-based evidence has also identified an association between co-trimoxazole use and sudden death among older patients receiving ACE inhibitors or ARBs. In a large nested case-control study, co-trimoxazole was associated with an adjusted odds ratio for sudden death of 1.38 within seven days and 1.54 within 14 days compared with amoxicillin; the investigators proposed unrecognised severe hyperkalaemia as a likely mechanism. Because this was an observational study, the finding represents an association rather than definitive proof of causation.